Related Experiment Video
Updated: Feb 27, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer]
Danjing Luo1, Jin'an Ma1, Jinming Zhang2
1Department of Oncology, The Second Xiangya Hospital, Center South University, Changsha 410011, China.
Abstract:
An ever increasing number of drugs directed as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) bring a new revolution for non-small cell lung cancer (NSCLC) therapy, and many large scales of studies show that only people with EGFR-sensitive mutation can benefit from these drugs. The main method of EGFR mutation detection is to analyze the DNA sequence of EGFR, which can be the lung cancer tissue, pleural fluid tumor cells, circulating tumor cells and peripheral blood free DNA obtained by surgery or puncture, the biggest drawback is that the heterogeneity of EGFR mutation cannot be analyzed. However, with the development of molecular imaging, the development of EGFR-targeted molecular probes based on positron emission computed tomography-computed tomography (PET-CT) has made it possible to reveal the EGFR mutations in lung cancer tissues in vivo, and can detect the heterogeneity of EGFR mutations. This article reviews all the results and progress of molecular probes targeting EGFR mutations.
Insights
Molecular imaging with EGFR-targeted probes revolutionizes non-small cell lung cancer (NSCLC) treatment by enabling in vivo detection of epidermal growth factor receptor (EGFR) mutations and their heterogeneity, improving targeted therapy efficacy.
Area of Science:
- Oncology
- Molecular Imaging
- Genetics
Background:
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) offer revolutionary non-small cell lung cancer (NSCLC) therapy, but efficacy is limited to patients with specific EGFR mutations.
- Current EGFR mutation detection methods analyze DNA from tissue or bodily fluids but cannot assess mutation heterogeneity.
- EGFR mutation heterogeneity is a critical factor influencing treatment response and patient outcomes in NSCLC.
Purpose of the Study:
- To review the advancements and applications of molecular probes targeting EGFR mutations for in vivo imaging in NSCLC.
- To highlight the potential of molecular imaging in overcoming the limitations of conventional EGFR mutation detection methods.
- To discuss the progress in developing PET-CT based molecular probes for visualizing EGFR mutations and heterogeneity.
Main Methods:
- Review of existing literature on EGFR-targeted molecular probes and their application in PET-CT imaging.
- Analysis of studies demonstrating the capability of molecular probes to detect EGFR mutations in vivo.
- Evaluation of the progress in probe development for visualizing EGFR mutation heterogeneity.
Main Results:
- Molecular imaging with EGFR-targeted probes enables non-invasive, in vivo visualization of EGFR mutations in NSCLC.
- Positron emission computed tomography-computed tomography (PET-CT) based probes can reveal EGFR mutation heterogeneity within tumors.
- This approach offers a significant advantage over conventional methods limited by intratumoral heterogeneity.
Conclusions:
- EGFR-targeted molecular probes represent a significant advancement in NSCLC diagnostics and personalized medicine.
- In vivo detection of EGFR mutation heterogeneity using molecular imaging can guide EGFR-TKI therapy selection and management.
- Further development of these probes promises to enhance treatment strategies and improve outcomes for NSCLC patients.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023